From: Predictors of fatality including radiographic findings in adults with COVID-19
Week 1 (≤ 7d) after symptom onset | Week 2 (> 7d, ≤ 14d) | Week 3(>14d, ≤ 21d) | Week 4(>21d, ≤ 28d) | ||
---|---|---|---|---|---|
Survivor (n = 21) | Non-Survivor (n = 11) | Survivor(n = 22) | Survivor(n = 25) | Survivor(n = 23) | |
Severity score of each lobe | |||||
Right upper lobe | 1 (0–1.5) | 3 (2–4)*** | 2 (1–2) | 1 (0.5–2) | 1 (0–2) |
Right middle lobe | 0 (0–1) | 2 (1–2) | 1 (0–1) | 0 (0–1) | 0 (0–1) |
Right lower lobe | 1 (1–3) | 3 (3–4) | 2.5 (1–3) | 1 (1–2.5) | 1 (1–2) |
Left upper lobe | 1 (0–1.5) | 3 (1–4) | 1.5 (0–3) | 1 (0–2) | 1 (0–2) |
Left lower lobe | 1 (0–2.5) | 4 (3–5)*** | 2 (1–3.25) | 1 (1–2.5) | 1 (0–2) |
Total severity score | 4 (2–9.5) | 15 (9–19)**** | 8 (4–12.25) | 5 (3–10) | 4 (2–9) |
< 15 | 20 (95.24%) | 4 (36.36%)*** | 19 (86.36%) | 23 (92%) | 22 (95.65%) |
≥ 15 | 1 (4.76%) | 7 (63.64%) | 3 (13.64%) | 2 (8%) | 1 (4.35%) |
Number of involved lobes | 3 (1.5–5) | 5 (4–5)** | 4.5 (3–5) | 4 (3–5) | 3 (2–5) |
< 5 | 14 (66.67%) | 2 (18.18%)* | 11 (50%) | 15 (60%) | 14 (60.87%) |
= 5 | 7 (33.33%) | 9 (81.82%) | 11 (50%) | 10 (40%) | 9 (39.13%) |
Lung involvement | |||||
No involvement | 2 (9.52%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Unilateral | 4 (19.05%) | 0 (0%) | 0 (0%) | 4 (16%) | 3 (13.04%) |
Bilateral | 15 (71.43%) | 11 (100%) | 22 (100%) | 21 (84%) | 20 (86.96%) |
Patterns of opacification | |||||
Ground glass opacity | 20 (95.24%) | 10 (90.91%) | 21 (95.45%) | 18 (72%) | 20 (86.96%) |
Crazy-paving pattern | 2 (9.52%) | 5 (45.45%)* | 5 (22.72%) | 3 (12%) | 4 (17.39%) |
Consolidation | 9 (42.86%) | 9 (81.82%) | 15 (68.19%) | 14 (56%) | 1 (4.35%)** |
Reticulation | 0 (0%) | 2 (18.18%) | 3 (13.64%) | 9 (36%)** | 15 (65.22%)**** |
Pleural effusion | 1 (4.76%) | 3 (27.27%) | 1 (4.55%) | 0 (0%) | 0 (0%) |
Distribution of opacification | |||||
No lesion | 2 (9.52%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Peripheral | 10 (47.62%) | 8 (72.73%) | 13 (59.09%) | 18 (72%) | 17 (73.91%) |
Random | 6 (28.57%) | 0 (0%) | 2 (9.09%) | 0 (0%)** | 0 (0%)** |
Diffuse | 3 (14.29%) | 3 (21.27%) | 7 (31.82%) | 7 (28%) | 6 (26.09%) |
Time between symptom onset and CT scan | 4 (2.5–5) | 5 (2–6) | 11.5 (9–13.25) | 18 (16–20) | 26 (24–28) |